|
gptkbp:instanceOf
|
gptkb:chemical_compound
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01XE01
|
|
gptkbp:bioavailability
|
98%
|
|
gptkbp:CASNumber
|
gptkb:146612-99-9
|
|
gptkbp:developedBy
|
gptkb:Novartis
|
|
gptkbp:eliminationHalfLife
|
18 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasInChIKey
|
gptkb:KHGXJUYNMMXHFG-UHFFFAOYSA-N
|
|
gptkbp:hasMolecularFormula
|
C29H31N7O
|
|
gptkbp:hasSMILES
|
CC1=CC(=C(C=C1)NC2=NC=NC(=C2)C3=CN=CC=C3)C(=O)NC4=CC=C(C=C4)CN5CCN(CC5)C
|
|
gptkbp:IUPACName
|
gptkb:4-[(4-methylpiperazin-1-yl)methyl]-N-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]benzamide
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
gptkb:receptor_tyrosine_kinase
|
|
gptkbp:metabolism
|
liver (CYP3A4)
|
|
gptkbp:molecularWeight
|
493.6 g/mol
|
|
gptkbp:name
|
gptkb:Imatinib
|
|
gptkbp:proteinBinding
|
95%
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:synonym
|
gptkb:Gleevec
gptkb:Glivec
gptkb:STI571
|
|
gptkbp:target
|
gptkb:BCR-ABL
gptkb:PDGFR
gptkb:c-KIT
|
|
gptkbp:usedFor
|
treatment of chronic myeloid leukemia
treatment of gastrointestinal stromal tumors
|
|
gptkbp:bfsParent
|
gptkb:reslizumab
|
|
gptkbp:bfsLayer
|
7
|
|
http://www.w3.org/2000/01/rdf-schema#label
|
146612-99-9
|